tbuckley/cabot-search huggingface dataset:
GOITERS IN TWINS RESULTING FROM PROPYLTHIOURACIL GIVEN DURING PREGNANCY
Authors: L K BRANCH, S W TUTHILL
Journal: Annals of Internal Medicine (1957)

Case Reports1 January 1957GOITERS IN TWINS RESULTING FROM PROPYLTHIOURACIL GIVEN DURING PREGNANCYLEROY K. BRANCH, M.D., SANFORD W. TUTHILL, M.D.LEROY K. BRANCH, M.D.Search for more papers by this author, SANFORD W. TUTHILL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-1-145 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThese cases warrant comment since no report has appeared in which twins were born with goiters iatrogenically produced with propylthiouracil and iodine. No clinical evidence of hypothyroidism appeared in the infants.CASE REPORTA three months pregnant, 41 year old white female had complained of increasing nervousness, severe palpitation, easier fatigue, weakness and increased sweating for several months. There was no history of diarrhea, heat intolerance, insomnia or previous symptoms to suggest thyroid dysfunction. Examination revealed an apprehensive patient with a resting pulse rate of 138 beats per minute. After one hour's rest the pulse rate was 120. A mild...Bibliography1. FreieslebenKjerulf-Jensen EK: The effect of thiouracil derivatives on fetuses and infants, J. Clin. Endocrinol. 7: 47, 1947. CrossrefGoogle Scholar2. Morris D: Transient hypothyroidism in a newborn infant, Lancet 1: 1284, 1953. CrossrefMedlineGoogle Scholar3. Blattner RJ: Hyperthyroidism, J. Pediat. 40: 679 (May) 1952. CrossrefMedlineGoogle Scholar4. Hepner WR: Thiourea derivatives and the fetus; a review and report of a case, Am. J. Obstet. and Gynec. 63: 869-873 (Apr.) 1952. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bogalusa, Louisiana*Received for publication July 18, 1955.From the Department of Pediatrics, Tulane University School of Medicine, and the Department of Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana.Requests for reprints should be addressed to S. W. Tuthill, M.D., 201 Louisiana Avenue, Bogalusa, Louisiana. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPropylthiouracilHyperthyroidism during PregnancyENVIRONMENTAL CARCINOGENESIS IN MAN AND ANIMALSHyperthyroidism and PregnancyDie Klinik der Mißbildungen und Mißbildungskrankheiten 1 January 1957Volume 46, Issue 1Page: 145-148KeywordsDiarrheaFatigueHeart rateHypothyroidismInfantsInsomniaPediatricsPregnancyThyroidTwins ePublished: 1 December 2008 Issue Published: 1 January 1957 PDF downloadLoading ...
Abstract 19396: Impaired Autonomic Modulation During the Valsalva Maneuver Predicts Ischemia in Patients With Coronary Artery Disease
Authors: Amit J Shah, Ayman Alkhoder, Malik Obideen, Ronnie Ramadan, Kobina Wilmot, Ibhar Al Mheid, Michael Kutner, Arshed A Quyyumi, J. Douglas Bremner, Viola Vaccarino
Journal: Circulation (2014)

Introduction: Previous studies have found that lower resting short-term heart rate variability (HRV), a measure of autonomic dysfunction, predicts adverse cardiac events. Abnormal autonomic function may precipitate myocardial ischemia. Physiologic challenges like Valsalva and deep breathing may also provide important data by modulating preload/afterload and stimulating various autonomic receptors. Methods: We examined autonomic function in 166 patients with CAD using the ANSAR method (ANX 3.0, ANSAR Inc. Philadelphia, PA). HRV was measured in the sitting position, standing position, during deep breathing, and during Valsalva. After ANSAR testing, patients underwent 99m Tc[[Unable to Display Character: &amp;#8208;]]sestamibi myocardial perfusion imaging at rest and with exercise or pharmacological stress. A summed difference score (SDS) was computed to quantify ischemia using a 17-segment model with observer-independent software. Multivariable models adjusted for CAD risk factors, psychiatric comorbidities, and medications. Results: The mean (SD) age was 62 (9) years, 75% were men, and 31% had ischemia (SDS ≥ 4). Both low (LF) and high (HF) frequency HRV during all 4 conditions were associated with ischemia in unadjusted models (table), but after multivariable adjustment, only LF and HF HRV during Valsalva and deep breathing were still associated with ischemia. The strongest association was found with LF HRV during Valsalva, such that every 10% decrease in LF HRV during Valsalva (p=0.003, adjusted) associated with a 1 point increase in SDS. When dividing patients into 4 categories of SDS score (0, 1-3, 4-7, ≥ 8), the SDS ≥ 8 category had a lower LF HRV during Valsalva than all other categories, most notably compared to SDS=0 (78% reduction in LF HRV). Conclusion: Low HF and LF HRV are associated with increased risk of myocardial ischemia in CAD patients. Most notably, autonomic inflexibility during Valsalva may help uncover underlying vulnerabilities in autonomic reflexes that predict ischemia burden.
Understanding breakage in curly hair
Authors: G.A. Camacho-Bragado, G. Balooch, F. Dixon-Parks, C. Porter, H. Bryant
Journal: British Journal of Dermatology (2015)

Journal Article Understanding breakage in curly hair Get access G.A. Camacho‐Bragado, G.A. Camacho‐Bragado The L'Oréal Institute for Ethnic Hair and Skin Research Chicago IL U.S.A Correspondence G. Alejandra Camacho‐Bragado. E‐mail: acamacho@rd.us.lorea.com Search for other works by this author on: Oxford Academic Google Scholar G. Balooch, G. Balooch L'Oreal Research and Innovation Clark NJ U.S.A Search for other works by this author on: Oxford Academic Google Scholar F. Dixon‐Parks, F. Dixon‐Parks The L'Oréal Institute for Ethnic Hair and Skin Research Chicago IL U.S.A Search for other works by this author on: Oxford Academic Google Scholar C. Porter, C. Porter The L'Oréal Institute for Ethnic Hair and Skin Research Chicago IL U.S.A Search for other works by this author on: Oxford Academic Google Scholar H. Bryant H. Bryant L'Oreal Research and Innovation Clark NJ U.S.A Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 173, Issue S2, 1 July 2015, Pages 10–16, https://doi.org/10.1111/bjd.13241 Published: 01 July 2015
Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease
Authors: M Fisman, H Mersky, E Helmes
Journal: American Journal of Psychiatry (1981)

A double-blind, placebo-controlled trial of 2-dimethylaminoethanol was undertaken in 27 patients with moderately severe or severe Alzheimer's disease. Of 13 patients in the drug group, 6 were withdrawn in the first 5 weeks of the trial because of side effects, which included drowsiness and retardation, with an increase of confusion and mild elevation of blood pressure. No significant benefit appeared from the drug treatment.
Abstract B57: miR-34 mimics synergize with small molecule inhibitors targeting the EGFR and Raf kinase pathways
Authors: Jane Zhao, Kevin Kelnar, Chris Daige, Jason Wiggins, Leslie Priddy, Terri Muenzer, Julie Tran, David Brown, Andreas G. Bader
Journal: Clinical Cancer Research (2015)

Abstract Sorafenib (Nexavar®) and erlotinib (Tarceva®) are FDA-approved therapies for patients with hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC), respectively. Sorafenib is a multi-kinase inhibitor targeting the Raf/Mek/Erk pathway, and erlotinib is a tyrosine kinase inhibitor antagonizing epidermal growth factor receptor (EGFR). Due to their selective inhibitory action and observed toxicities, current treatment options for liver and lung cancer are limited and many cancers develop resistance. Naturally occurring tumor suppressor microRNAs inhibit tumor growth by regulating multiple oncogenes at once and, therefore, microRNA mimics, which are copies of the naturally occurring microRNAs, may be used in combination with the respective standard of care drugs to bring this tumor suppressor activity back into tumor cells and thereby augment drug sensitivity. Here, we investigated the relationship of a mimic of the tumor suppressor microRNA miR-34 in combination with erlotinib or sorafenib and determined the therapeutic activity of the combination in lung and liver cancer cells. Data derived from isobolograms, combination index plots and curve shift analyses indicate synergy in all cancer cell lines tested. Synergy was observed at multiple microRNA and drug ratios and at drug concentrations that induce 50% or greater cancer cell inhibition. Data from cell and animal studies will be presented. Citation Format: Jane Zhao, Kevin Kelnar, Chris Daige, Jason Wiggins, Leslie Priddy, Terri Muenzer, Julie Tran, David Brown, Andreas G. Bader. miR-34 mimics synergize with small molecule inhibitors targeting the EGFR and Raf kinase pathways. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr B57.
The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways
Authors: Armen N. Akopian, Veronika Souslova, Steven England, Kenji Okuse, Nobukuni Ogata, Jan Ure, Andrew Smith, Bradley J. Kerr, Steven B. McMahon, Sue Boyce, Ray Hill, Louise C. Stanfa, Anthony H. Dickenson, John N. Wood
Journal: Nature Neuroscience (1999)
Abstract 221: Prognostic Impact of Estimated Glomerular Filtration Rate in Patients with Percutaneous Veno-arterial Extracorporeal Membrane Oxygenation
Authors: Norihiro Kuroki, Daisuke Abe, Koichi Ohashi, Kazuki Miyazaki, Kazuya Tateishi, Masakazu Kaneko, Tomohiko Harunari, Takao Yuba, Kazuhiro Sugiyama, Akiko Akashi, Kou Suzuki, Yuichi Hamabe, Toru Iwama
Journal: Circulation (2014)

Purpose: Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) has been reported to improve survival in patients with cardiogenic shock or cardiac arrest. We investigated the association between initial renal function just before implantation and clinical outcome in patients undergoing VA-ECMO due to cardiogenic shock and cardiac arrest. Methods: A cohort of 212 patients (58.8±16.2 years old, 86% male) who underwent ECMO at our hospital was registered from January 2007 to December 2013. We excluded 68 patients caused by non-cardiogenic event. The remaining 144 patients (91 with acute myocardial infarction, 37 with refractory ventricular fibrillation, 6 with refractory congestive heart failure, and 6 with fulminant myocarditis) were divided into 2 groups according to initial estimated-glomerular filtration rate (eGFR). Non-CKD Group: eGFR ≥60ml/min/1.73m 2 (n=98); CKD Group: eGFR &lt;60 (n=46). Clinical outcome was defined as all-cause death at discharge. Results: The 82% of patients received VA-ECMO due to cardiac arrest. In baseline characteristics, Non-CKD group was significantly younger (50.4 vs. 62.8 years old), lower incidence of hypertension in past history (26.1 vs.52.0 %), lower BUN (13.7 vs. 24.3 mg/dl), and lower K (3.9 vs. 4.5 mEq/l, all p&lt;0.05) than CKD group. Incidence of all-cause death was significantly lower in Non-CKD group than in CKD group (Non-CKD vs. CKD: 60.9% vs. 78.6%: p=0.026) (Figure). The low eGFR was an independent predictor of mortality after adjustment of multiple cofounders (eGFR &lt;60, OR: 2.87, 95% confidence interval: 1.04-7.94, p=0.042). Negative independent predictors of mortality were fulminant myocarditis (OR: 0.08, 95% CI: 0.007-0.99, p=0.049) and count of platelet (per increase, OR: 0.94, 95% confidence interval: 0.88-0.99, p=0.037) Conclusion: Initial low e-GFR just before implantation provides worse clinical outcome in patients with VA-ECMO due to cardiogenic shock and cardiac arrest.
Abstract 2412: Chronic Vagus Nerve Stimulation in Patients with Chronic Heart Failure is Feasible and Appears Beneficial
Authors: Gaetano M De Ferrari, Antonio Sanzo, Martin Borggrefe, Christian Wolpert, Jürgen Kuschyk, Antonina Schöne, Harry J Crijns, Robert Dennert, Goran Milasinovic, Srdjan Raspopovic, Helmut Klein, Jan Smid, Antonello Gavazzi, Attilio Iacovoni, Ospedali Riuniti, Markus Zabel, Peter J Schwartz
Journal: Circulation (2008)

Introduction Enhancement of vagal nerve activity has a strong experimental rationale as a potential therapeutic approach to patients with severe Congestive Heart Failure (CHF). The CardioFit (BioControl Medical, Ltd.) is an implantable system capable of delivering chronic vagus nerve stimulation (CVNS) synchronized with the heart beat via a multipolar stimulation lead. Methods Twenty-nine patients with stable CHF, NYHA class II–IV, LVEF ≤ 35% on optimal medical therapy were enrolled and successfully implanted in a 7-site international 6-month safety and efficacy pilot study. Optimization of CVNS parameters occurred during a four week run-in period, two to four weeks post-implantation. Results Twenty subjects (mean age 57 years, range 30 –75; ischemic etiology in 70%; prior ICD in 50%) completed six-month follow-up; one NYHA class IV subject died due to worsening HF two months after implantation. At 6-months, 14 subjects had improved their NYHA class, and 6 remained stable. A significant improvement (p &lt; 0.05) was found in the subjects’ quality of life (MLwHF® questionnaire); exercise capacity (6-minute walk test; see graph); and blindly evaluated LV ejection fraction (from 24 ± 2% to 29 ± 2%). The most commonly reported transient adverse events were expected side-effects of CVNS such as pain at cuff site (n = 6), cough (n = 7), and voice alteration (n = 5), which were resolved by optimizing stimulation parameters. Conclusions Chronic Vagus Nerve Stimulation in patients with advanced heart failure is feasible and appears to be well tolerated and safe. Initial data suggest a favorable trend of clinical outcomes. At this point a large scale randomized controlled study is warranted.
724. Engineering of Vesicular Stomatitis Virus-G Protein (VSV-G) To Retarget Recombinant Infectious Retroviral Particles
Authors: Julie H. Yu, David V. Schaffer
Journal: Molecular Therapy (2004)

Several obstacles still need to be overcome before retroviral vectors can be used in a wide clinical application. Engineering of these viruses by inserting novel protein or peptide sequences into several viral proteins could readily enhance their properties and features for gene delivery. However, it is difficult to rationally determine where within a protein to insert a new sequence without disrupting the core ability of the virus to transduce cells. We have developed a system to modify viral genomes through the random insertion of small peptides that may confer novel function to the viral vector. This high throughput method generates a library of proteins that have a specifically designed peptide or protein sequence incorporated at as many or all possible points in the sequence of the original protein. We can then use a directed evolution approach and screen these libraries to identify tolerable insertion sites that may yield a desired function. We have used this method to generate insertional libraries of two important genes: the Moloney murine leukemia virus (MoMLV) gag-pol gene, which encodes for most of the structural and functional proteins of the virus, and the gene that encodes for the vesicular stomatitis virus G protein (VSV-G), an envelope protein commonly used to pseudotype simple retroviral and lentiviral vectors. We are using these libraries to explore the addition of novel features to MoMLV for gene delivery applications. These features address some of the major limitations of retroviral vectors including delivery to non-dividing cells, tissue specific targeting, and purification. Identification of mutants with enhanced function will allow us to generate a more effective and efficient retroviral vector. Furthermore, the detailed genetic footprint provided by the comprehensive coverage of insertion sites will give us additional knowledge of the function of these specific genes and their associated proteins.
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability
Authors: Catherine S. Healey, Alison M. Dunning, M. Dawn Teare, Diana Chase, Louise Parker, John Burn, Jenny Chang-Claude, Arto Mannermaa, Vesa Kataja, David G. Huntsman, Paul D.P. Pharoah, Robert N. Luben, Douglas F. Easton, Bruce A.J. Ponder
Journal: Nature Genetics (2000)
EvidenceNOW Grants Focus on Heart Disease Care in Small Practices
Authors: Laura Buchholz
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IgE and IgG cross‐reactivity among <i>Lol p</i> I and <i>Lol p</i> II/III
Authors: R. van Ree, W. A. van Leeuwen, M. van den Berg, H. H. Weller, R. C. Aalberse
Journal: Allergy (1994)

In this study, the homologous C‐termini of Lol p I Lol p II, and Lol p III were shown to contain cross‐reactive B‐cell epitopes. This was demonstrated by inhibition studies with purified Lol p I, II, and III and synthetic peptides of their C‐termini. It was ruled out that the observed cross‐reactivity was caused by cross‐contamination of the purified allergens. Both human IgE and IgG bound to the C‐terminus of Lol p I. These antibodies were cross‐reactive with Lol p II and, more specifically, with its C‐terminus. Within a small panel of allergic patients, no cross‐reactivity with Lol p III was found. A hyperimmune polyclonal rabbit antiserum against Lol p I also recognized the Lol p I C‐terminus. As for human antibodies, cross‐reactivity with Lol p II and its C‐terminus was demonstrated. Cross‐reactivity with Lol p III was demonstrated with C‐terminal peptides, but not with native Lol p III. A polyclonal rabbit antiserum against Lol p II bound to the C‐terminal peptides of both Lol p II and III. This binding was inhibited with Lol p I, confirming that cross‐reactive structures exist not only on the C‐termini of Lol p II and Lol p I, but also of Lol p III and Lol p I. The existence of cross‐reactivity between Lol p I and Lol p II and III possibly contributes to the frequently observed cosensitization for these allergens in grass‐pollen‐allergic patients.
Abstract P263: Central Obesity and the Emerging Epidemic of Type 2 Diabetes in Saudi Arabia
Authors: Lena Al Khudairy, Karen Rees, Sudhesh Kumar, Nasser Al-Daghri, Omar Al Attas, Majid Al Okail, Khalid Al Kharfy, Saverio Stranges
Journal: Circulation (2015)

Introduction:  Obesity is considered to be one of the most significant emerging public health problems in Saudi Arabia. Saudi Arabia is in the top ten countries as to the prevalence of obesity (35.6%) and diabetes (31.6%). However, the associations between different obesity measures and type 2 diabetes mellitus (T2DM) have not been extensively investigated within the Saudi context.   Objective:  We sought to examine the cross-sectional associations between measures of body weight and body fat distribution such as body mass index (BMI), waist circumference (WC) and T2DM prevalence in Saudi adults.   Methods:  This study was based on 2355 Saudi adults (≥18 years), part of a larger sample of 14,060 participants randomly selected from a roster of 150 primary health care centers (PHCC’s) of Riyadh city, Saudi Arabia. For each PHCC, a physician invited participants from randomly selected households (alternate houses). The number of subjects sampled from each PHCC was dependent on the total population assigned to the respective PHCC.  Physicians confirmed diabetes diagnosis by either following World Health Organization proposed cut-off values (fasting plasma glucose levels ≥ 7.0 mmol/L) and/or self-report of anti-diabetes medications.  For the overall sample and for men and women separately, logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CI) of T2DM prevalence across BMI groups and WC tertiles. The reference category was the lowest. Covariates included: age, sex, marital status, education level, family history of diabetes, physical activity, caloric intake, and history of gestational diabetes (GDM) in females.   Results:  The overall prevalence of T2DM was 29.3% (25.4% in females vs. 32.9% in males). Obese females (BMI ≥ 30 kg/m 2 ) had an OR of 3.39 (95% CI, 1.5-7.6,  p  = 0.001) for diagnosed T2DM, whilst obese males (BMI ≥ 30 kg/m 2 ) had a borderline association with T2DM (OR 1.41, 95% CI, 0.8-2.2,  p  = 0.077).  Higher values of WC were associated with T2DM in both females and males. However, males with a higher WC (≥ 104 cm) had a significant association with T2DM even after multivariate adjustment (OR 1.99, 95% CI, 1.2-3.1,  p  = 0.006).  In the overall sample, a direct and statistically significant ( p  = 0.014) association between the age-sex adjusted OR for T2DM and WC persisted within each group of BMI. However, this association was not significant ( p  = 0.572) between BMI and T2DM across tertiles of WC.   Conclusion:  Results suggest that measures of central adiposity, indicated by WC, are associated with diabetes, independently of BMI, whereas the associations of BMI with diabetes is greatly attenuated after accounting for body fat distribution.